Xeris Pharmaceuticals | XERS - Ebit


Xeris Pharmaceuticals reported $9.12M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Celltrion KRW 13.41B 1.33B Mar/2026
Cspc Pharmaceutical CNY 206.26M 1.02B Dec/2025
Deva Holding AS TRY 820.88M 192.13M Sep/2023
Dianthus Therapeutics USD -46.53M 23.01M Mar/2026
Divis Laboratories Ltd INR 11.29B 3.15B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Kangmei Pharma CNY -12.72M 13.97M Mar/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Laboratorios Farma EUR 135.05M 49.84M Dec/2023
Malin Corporation EUR -1.1M 300K Dec/2024
Medical Developments International AUD -36K 12.96M Dec/2025
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neuren Pharmaceuticals AUD 17.01M 154.09M Dec/2025
Organigram Holdings CAD -9.79M 10.33M Mar/2026
Ovoca Bio EUR -173K 990K Dec/2025
Pacira USD 9.96M 5.33M Jun/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pharma Mar EUR -1.4M 2.03M Jun/2026
Qiagen NV USD 96.88M 25M Mar/2026
Sartorius EUR 164M 3.3M Jun/2026
Sino Biopharmaceutical CNY 5.18B 3.32B Jun/2025
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Tilray USD -20.01M 9.34M Sep/2025
Zealand Pharma A/S -389M 318.05M Mar/2026
Zz Pientze Pharmaceu CNY 837.81M 336.48M Mar/2026